<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002281</url>
  </required_header>
  <id_info>
    <org_study_id>061A</org_study_id>
    <secondary_id>GCSF-8808-109</secondary_id>
    <nct_id>NCT00002281</nct_id>
  </id_info>
  <brief_title>A Study of Granulocyte Colony-Stimulating Factor Plus Recombinant Erythropoietin Plus Zidovudine in Patients With AIDS or AIDS-Related Complex</brief_title>
  <official_title>An Open Label Phase I/II Study of Recombinant Granulocyte Colony-Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With AIDS or ARC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerance and biological activity of filgrastim (granulocyte&#xD;
      colony-stimulating factor; G-CSF) given by daily subcutaneous (SC) injection prior to and&#xD;
      concomitantly with erythropoietin (EPO) and zidovudine (AZT) in patients with AIDS or severe&#xD;
      AIDS related complex (ARC). To evaluate the safety, tolerance, and biological activity of EPO&#xD;
      given 3 times weekly by SC injection concomitantly with G-CSF and prior to and concomitantly&#xD;
      with AZT in patients with AIDS or severe ARC. To study the safety and tolerance of 3 dose&#xD;
      levels of AZT given to patients with AIDS or severe ARC concomitantly treated with G-CSF and&#xD;
      EPO. To study the effect of G-CSF alone and in combination with EPO on HIV replication in&#xD;
      vivo as measured by circulating HIV p24 antigen, plasma HIV viremia and semiquantitative HIV&#xD;
      cocultures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>HIV Infections</condition>
  <condition>Cytopenias</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Radiation or laser therapy to Kaposi's sarcoma lesions provided the dose does not&#xD;
             exceed 3000 rads to any one lesion group and/or greater than 10 cm2 total body surface&#xD;
             area.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  A diagnosis of AIDS or AIDS related complex (ARC) as defined by current CDC&#xD;
             guidelines.&#xD;
&#xD;
          -  Life expectancy &gt; 6 months.&#xD;
&#xD;
          -  Defined blood cell counts that may be achieved by transfusion.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  History of malignancy other than Kaposi's sarcoma (KS).&#xD;
&#xD;
          -  Presence of &gt; 50 cutaneous KS lesions or progression of KS over the previous 30 days.&#xD;
&#xD;
          -  Presence of opportunistic infection requiring ongoing therapy with known bone marrow&#xD;
             suppressive agents.&#xD;
&#xD;
          -  History of cardiovascular disease.&#xD;
&#xD;
          -  History of seizures.&#xD;
&#xD;
          -  HIV related dementia or altered mental status that would prohibit the giving and&#xD;
             understanding of informed consent.&#xD;
&#xD;
          -  Presence of iron deficiency anemia as defined by serum ferritin &lt; 30 ng or iron to&#xD;
             TIBC ratio &lt; 15 percent.&#xD;
&#xD;
          -  A PT &gt; 15 and a PTT &gt; 40 unless due to a documented circulating lupus anticoagulant.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Trimethoprim / sulfamethoxazole.&#xD;
&#xD;
          -  Fansidar.&#xD;
&#xD;
          -  Non-FDA approved antiretrovirals.&#xD;
&#xD;
          -  Hyperimmunization with polio virus.&#xD;
&#xD;
          -  Ribavirin.&#xD;
&#xD;
          -  Isoprinosine.&#xD;
&#xD;
          -  Dextran sulfate.&#xD;
&#xD;
          -  Fu zheng herbs.&#xD;
&#xD;
          -  AL 721 or its congeners.&#xD;
&#xD;
          -  Imuthiol.&#xD;
&#xD;
          -  Interferons.&#xD;
&#xD;
          -  Chronic use of acyclovir (&gt; 10 days out of 30 days).&#xD;
&#xD;
          -  = or &gt; 3g/day oral vitamin C.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Co-existing conditions and symptoms described in Patient Exclusion Co-existing&#xD;
             Conditions.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 2 weeks of study entry:&#xD;
&#xD;
          -  Any non-FDA approved drug.&#xD;
&#xD;
          -  Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Systemic cytotoxic chemotherapy for Kaposi's sarcoma.&#xD;
&#xD;
          -  Investigational agents.&#xD;
&#xD;
          -  Excluded:&#xD;
&#xD;
          -  Colony stimulating factors.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Radiation therapy for Kaposi's sarcoma exceeding 3000 rads to any one lesion group&#xD;
             and/or greater than 10 cm2 total body surface area.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded within 3 months of study entry:&#xD;
&#xD;
          -  Regular excessive use of alcohol, hallucinogens or other psychotropic agents which are&#xD;
             possibly addicting.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Miles SA, Mitsuyasu RT, Moreno J, Baldwin G, Alton NK, Souza L, Glaspy JA. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood. 1991 May 15;77(10):2109-17.</citation>
    <PMID>1709368</PMID>
  </reference>
  <verification_date>January 1990</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Injections, Subcutaneous</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>AIDS-Related Complex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

